The registration phase III clinical trial of the novel BCL2 inhibitor Mesutoclax in combination with ibrutinib as first-line treatment for CLL/SLL has completed patient enrollment.

On February 26, Norchester announced that the company's independently developed novel BCL2 inhibitor mesutoclax, combined with the BTK inhibitor obinutuzumab, has completed patient enrollment in a phase III clinical trial for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.